Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN D versus PHENETRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN D versus PHENETRON.
CLARITIN-D vs PHENETRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1 receptor antagonism. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction.
Phenetron is an antihistamine that competes with histamine for H1-receptor sites, blocking histamine-mediated effects in the respiratory tract, vascular system, and gastrointestinal tract. It also exhibits anticholinergic and sedative properties.
One tablet (5 mg loratadine/120 mg pseudoephedrine sulfate) orally every 12 hours; do not exceed 2 tablets in 24 hours.
Adults: 50 mg intramuscularly every 6 hours as needed.
None Documented
None Documented
Loratadine: 8-14 h (mean 11 h); desloratadine: 17-24 h (mean 21 h). Pseudoephedrine: 4-8 h (mean 6 h), prolonged in alkaline urine.
Terminal half-life 12–15 hours; clinically, steady-state achieved in ~3 days
Loratadine: 40% renal (metabolites), ~40% fecal; desloratadine: 33% renal, 66% fecal. Pseudoephedrine: 70-90% renal unchanged, 1-2% biliary.
Renal: ~70% unchanged; Biliary/Fecal: ~15% as metabolites; 15% unidentified
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine